CN1142271C - 适应非洲绿猴肾细胞的减毒的日本脑炎病毒和其疫苗 - Google Patents

适应非洲绿猴肾细胞的减毒的日本脑炎病毒和其疫苗 Download PDF

Info

Publication number
CN1142271C
CN1142271C CNB988097974A CN98809797A CN1142271C CN 1142271 C CN1142271 C CN 1142271C CN B988097974 A CNB988097974 A CN B988097974A CN 98809797 A CN98809797 A CN 98809797A CN 1142271 C CN1142271 C CN 1142271C
Authority
CN
China
Prior art keywords
virus
vaccine
vero
vaccines
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB988097974A
Other languages
English (en)
Chinese (zh)
Other versions
CN1272879A (zh
Inventor
金炫洙
刘王敦
金寿玉
���ɿ������޹�˾
李星熙
文祥帆
洪璿杓
Ų�������޹������޹�˾
申营喆
郑用周
K·H·埃克尔斯
B·英尼斯
J·R·普特纳克
L·N·宾尼
A·K·斯里瓦斯塔瓦
D·R·杜波依斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reed Institute For Military Research
First Sugar Refining Corp
Original Assignee
Reed Institute For Military Research
First Sugar Refining Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reed Institute For Military Research, First Sugar Refining Corp filed Critical Reed Institute For Military Research
Publication of CN1272879A publication Critical patent/CN1272879A/zh
Application granted granted Critical
Publication of CN1142271C publication Critical patent/CN1142271C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CNB988097974A 1997-08-28 1998-08-25 适应非洲绿猴肾细胞的减毒的日本脑炎病毒和其疫苗 Expired - Lifetime CN1142271C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR1997/42002 1997-08-28
KR19970042002 1997-08-28
KR19970042001 1997-08-28
KR1997/42001 1997-08-28

Publications (2)

Publication Number Publication Date
CN1272879A CN1272879A (zh) 2000-11-08
CN1142271C true CN1142271C (zh) 2004-03-17

Family

ID=26633032

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB988097974A Expired - Lifetime CN1142271C (zh) 1997-08-28 1998-08-25 适应非洲绿猴肾细胞的减毒的日本脑炎病毒和其疫苗

Country Status (15)

Country Link
US (1) US6309650B1 (enExample)
EP (2) EP1604685B1 (enExample)
JP (1) JP4161017B2 (enExample)
KR (1) KR100314404B1 (enExample)
CN (1) CN1142271C (enExample)
AU (1) AU748730B2 (enExample)
CA (1) CA2301000C (enExample)
DE (2) DE122009000037I2 (enExample)
DK (2) DK1604685T3 (enExample)
ES (2) ES2382946T3 (enExample)
FR (1) FR09C0037I2 (enExample)
MY (1) MY129773A (enExample)
NL (1) NL300391I2 (enExample)
NZ (1) NZ503522A (enExample)
WO (1) WO1999011762A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100340596C (zh) * 2004-05-20 2007-10-03 佛山市顺德区汉达精密电子科技有限公司 回收聚碳酸酯/丙烯腈－丁二烯－苯乙烯共聚物及其回收方法

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000083657A (ja) * 1998-07-13 2000-03-28 Chemo Sero Therapeut Res Inst 日本脳炎ウイルスワクチン
CN1160454C (zh) * 1998-10-05 2004-08-04 财团法人阪大微生物病研究会 用于抗日本脑炎病毒感染的灭活疫苗的增强免疫原及其生产方法
ES2388909T3 (es) * 1999-04-22 2012-10-19 The United States Of America, As Represented Bythe Secretary Of Agriculture Vacuna contra el virus del síndrome respiratorio y reproductivo porcino basada en aislado JA-142 aislada
WO2001076624A1 (en) * 2000-04-07 2001-10-18 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Inactivated japanese b encephalitis vaccine and process for producing the same
EP1416986A4 (en) * 2001-06-29 2005-12-14 Becton Dickinson Co INTRADERMIC DISTRIBUTION OF VACCINES AND GENE THERAPEUTIC AGENTS VIA MICROCANNULE
JP2007068401A (ja) * 2003-08-07 2007-03-22 Chemo Sero Therapeut Res Inst 西ナイルウイルスワクチン
CN1922308A (zh) * 2004-02-23 2007-02-28 克鲁塞尔荷兰公司 病毒纯化方法
CA2602944C (en) * 2005-04-11 2015-08-11 Crucell Holland B.V. Virus purification using ultrafiltration
WO2008115314A2 (en) * 2007-01-31 2008-09-25 Sanofi Pasteur Biologics Co. Flavivirus vaccine vector against influenza virus
MY173418A (en) * 2007-12-26 2020-01-23 Daiichi Sankyo Co Ltd Method of producing japanese encephalitis avccines stably storable over long time and use of the vaccine
CN102112153B (zh) * 2008-06-04 2014-04-16 一般财团法人化学及血清疗法研究所 灭活日本脑炎病毒颗粒作为佐剂的用途
WO2010013601A1 (ja) * 2008-07-30 2010-02-04 久光製薬株式会社 マイクロニードルデバイスおよびマイクロニードルデバイスによる日本脳炎ウイルス抗原の奏功性を上昇させる方法
WO2010137036A2 (en) * 2009-05-25 2010-12-02 Panacea Biotec Ltd Novel japanese encephalitis vaccine and method of manufacturing the same
KR101144993B1 (ko) * 2009-06-18 2012-06-27 대한민국 돼지 일본뇌염 바이러스의 고농축 혈구응집용 항원
DK2788023T3 (en) 2011-12-06 2016-12-19 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
US9895437B2 (en) 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
RU2706693C2 (ru) * 2013-09-14 2019-11-20 Бхарат Байотек Интернэшнл Лимитед Вирусная вакцина и способы ее производства
CN105695424B (zh) * 2015-04-01 2019-06-14 中国食品药品检定研究院 乙型脑炎减毒活疫苗株sa14-14-2在人二倍体细胞2bs上的适应株及其疫苗
EP4253403A3 (en) 2015-12-23 2023-12-27 Valneva Austria GmbH Zika virus purification
US10881723B2 (en) 2016-01-15 2021-01-05 Km Biologics Co., Ltd. Vaccine containing immobilized virus particles
WO2017210215A1 (en) 2016-05-31 2017-12-07 The Government Of The United States Of America As Represented By The Secretary Of The Army Zika virus vaccine and methods of production
SG11202001161YA (en) 2017-09-21 2020-03-30 Valneva Se Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3
CA3081581A1 (en) 2017-11-03 2019-05-09 Takeda Vaccines, Inc. Method for inactivating zika virus and for determining the completeness of inactivation
AU2018375173B2 (en) 2017-11-30 2022-08-25 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
CN110684747B (zh) * 2018-07-06 2024-05-24 厦门大学 灭活及保存呼吸道合胞病毒的方法
US20210277361A1 (en) * 2018-08-27 2021-09-09 Mican Technologies Inc. Method for evaluating anti-infective drugs, vaccines, etc. using immortalized monocytic cells and induced cells
WO2021178306A1 (en) 2020-03-01 2021-09-10 Dynavax Technologies Corporation Coronavirus vaccines comprising a tlr9 agonist
EP3895729A1 (en) 2020-03-01 2021-10-20 Valneva Austria GmbH Cpg-adjuvanted sars-cov-2 virus vaccine
WO2021176434A1 (en) 2020-03-01 2021-09-10 Valneva Austria Gmbh Cpg-adjuvanted sars-cov-2 virus vaccine
WO2021204825A2 (en) 2020-04-06 2021-10-14 Valneva Austria Gmbh INACTIVATED SARS-CoV-2 VIRUS VACCINE
WO2023148256A1 (en) 2022-02-02 2023-08-10 Valneva Austria Gmbh Inactivated sars-cov-2 virus vaccine
EP4428231A4 (en) * 2022-04-20 2025-11-19 Korea Nat Institute Of Health GENOTYPE 5 OF HIGH-TIRES JAPANESE ENCEPHALITIS VIRUS AND ITS USE
EP4652265A1 (en) 2023-01-18 2025-11-26 Valneva Austria GmbH Process for virus production in a bioreactor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2704258B2 (ja) * 1987-10-31 1998-01-26 日本臓器製薬株式会社 組み換えワクチニアウイルス
GB8821656D0 (en) * 1988-09-15 1988-10-12 Health Lab Service Board Pharmaceutical compositions for eliciting immunostimulant effect
JPH085803B2 (ja) * 1988-11-10 1996-01-24 武田薬品工業株式会社 日本脳炎ワクチンの製造法
EP0562136A1 (en) * 1992-03-24 1993-09-29 Division Of Microbiology, Kyoto Biken Laboratories, Inc. Live vaccine to getah virus infectious disease, and trivalent live vaccine to Japanese encephalitis virus, porcine parvovirus and getah virus infectious diseases
US6010894A (en) * 1997-06-13 2000-01-04 Research Development Foundation Method of screening for attenuating viruses

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100340596C (zh) * 2004-05-20 2007-10-03 佛山市顺德区汉达精密电子科技有限公司 回收聚碳酸酯/丙烯腈－丁二烯－苯乙烯共聚物及其回收方法

Also Published As

Publication number Publication date
KR19990023955A (ko) 1999-03-25
WO1999011762A1 (en) 1999-03-11
ES2382946T3 (es) 2012-06-14
DE69837211D1 (de) 2007-04-12
CA2301000C (en) 2003-07-08
AU748730B2 (en) 2002-06-13
JP4161017B2 (ja) 2008-10-08
EP1025209B1 (en) 2007-02-28
US6309650B1 (en) 2001-10-30
DK1604685T3 (da) 2012-06-18
NZ503522A (en) 2001-06-29
DE122009000037I1 (de) 2009-11-05
DE69837211T2 (de) 2007-12-06
FR09C0037I2 (fr) 2021-11-05
EP1604685B1 (en) 2012-02-22
AU9004798A (en) 1999-03-22
KR100314404B1 (ko) 2002-10-12
CA2301000A1 (en) 1999-03-11
FR09C0037I1 (enExample) 2009-09-25
MY129773A (en) 2007-04-30
ES2281929T3 (es) 2007-10-01
NL300391I1 (nl) 2009-08-03
DK1025209T3 (da) 2007-06-25
NL300391I2 (nl) 2009-11-02
EP1025209A1 (en) 2000-08-09
EP1604685A2 (en) 2005-12-14
CN1272879A (zh) 2000-11-08
DE122009000037I2 (de) 2011-06-16
JP2001514844A (ja) 2001-09-18
EP1604685A3 (en) 2006-07-05

Similar Documents

Publication Publication Date Title
CN1142271C (zh) 适应非洲绿猴肾细胞的减毒的日本脑炎病毒和其疫苗
AU2016375338B2 (en) Zika virus vaccine
JP5095685B2 (ja) 日本脳炎ウイルス群感染症に対する不活化ワクチンのための増強免疫原およびその製造方法
JP2011507523A (ja) 遺伝子改変した弱毒化水疱性口内炎ウイルス、組成物およびその使用方法
CN1867355A (zh) 包含诱导粘膜免疫的佐剂的新型疫苗
CN1345775A (zh) 用于预防、诊断及治疗戊型肝炎病毒的多肽,及它们作为诊断试剂和疫苗
CN109536460A (zh) 一种cv-a10病毒毒种及其人用灭活疫苗
JPWO2000020565A1 (ja) 日本脳炎ウイルス群感染症に対する不活化ワクチンのための増強免疫原およびその製造方法
CN112592409B (zh) 猪繁殖与呼吸综合症病毒基因工程亚单位疫苗
WO2019163781A1 (ja) エンテロウイルスワクチン
CN109609467A (zh) 一种cv-a6病毒毒种及其人用灭活疫苗
US20250325645A1 (en) Bovine viral diarrhea virus immunogenic compositions and methods of use thereof
CN1150819A (zh) 含有jeryl-lynn病毒株的抗流行性腮腺炎疫苗
CN1185254C (zh) 丙型肝炎病毒第一高变区抗原及其融合抗原
RU2603729C2 (ru) Рекомбинантная вакцина для профилактики вирусного гепатита в (варианты)
CN1429235A (zh) 蜱传黄病毒的全长感染性cDNA克隆
CN1778812A (zh) 重组杆状病毒表达的诺瓦克样病毒衣壳蛋白及其制备方法
TWI228147B (en) An attenuated Japanese encephalitis virus adapted to Vero cell and a Japanese encephalitis vaccine
CN1137896C (zh) 新型口蹄疫疫苗及其制备方法
CN1513553A (zh) Vero细胞森林脑炎灭活疫苗
CN1871026A (zh) 黄病毒疫苗

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CI01 Publication of corrected invention patent application

Correction item: Priority

Correct: 1997.08.28 KR 1997/42001|1997.08.28 KR 1997/42002

False: 1997.08.28 KR 1997/42001

Number: 11

Page: 397

Volume: 20

CI03 Correction of invention patent

Correction item: Priority

Correct: 1997.08.28 KR 1997/42001|1997.8.28 KR 1997/42002

False: 1997.08.28 KR 1997/42001

Number: 11

Page: The title page

Volume: 20

COR Change of bibliographic data

Free format text: CORRECT: PRIORITY; FROM: 1997.8.28 KR 1997/42001 TO: 1997.8.28 KR 1997/42001 1997.8.28 KR 1997/42002

ERR Gazette correction

Free format text: CORRECT: PRIORITY; FROM: 1997.8.28 KR 1997/42001 TO: 1997.8.28 KR 1997/42001 1997.8.28 KR 1997/42002

CI01 Publication of corrected invention patent application

Correction item: Priority

Correct: 1997.08.28 KR 1997/42002

False: Second missing

Number: 11

Volume: 20

CI03 Correction of invention patent

Correction item: Priority

Correct: 1997.08.28 KR 1997/42002

False: Second missing

Number: 11

Page: The title page

Volume: 20

COR Change of bibliographic data

Free format text: CORRECT: PRIORITY; FROM: LACK NO. 2 TO: 1997.8.28 KR 1997/42002

ERR Gazette correction

Free format text: CORRECT: PRIORITY; FROM: LACK NO. 2 TO: 1997.8.28 KR 1997/42002

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1060797

Country of ref document: HK

CX01 Expiry of patent term

Granted publication date: 20040317

CX01 Expiry of patent term